M Lüftl1, G Schuler, A A Jungbluth. 1. Department of Dermatology, University Hospital of Erlangen, Hartmannstrasse 14, D-91052 Erlangen, Germany. matthias.lueftl@derma.imed.uni-erlangen.de
Abstract
BACKGROUND: Cancer testis antigens (CTAs) are expressed in a variety of malignant tumours. No CTA expression is found in normal adult tissues, except in male germ cells and occasionally placenta. To date, more than 20 CTAs or antigen families have been identified. OBJECTIVES: Owing to their tumour-associated expression pattern, CTAs may be useful for making a distinction between benign and malignant neoplasms. The present study was done to analyse the value of CTAs for the discrimination of cutaneous melanoma and naevi. PATIENTS AND METHODS: Primary melanomas (38) and 19 naevi were analysed for their expression of CTAs by immunohistochemistry using the following monoclonal antibodies (mAb) to the following antigens (mAb/antigen): MA454/MAGE-A1, 57B/MAGE-A4, ES121/NY-ESO-1. In a subset of melanomas (n = 26), the CTA panel was extended to three additional CTAs (mAb/antigen): CT7-33/MAGE-C1, M3H67/MAGE-A3 and GAGE/GAGE. RESULTS: All 19 naevi were negative for the mAbs MA454, M3H67, 57B, ES121, CT7-33 and GAGE. In melanoma, the immunoreactivity was as follows: MA454: 8/38 (21%), 57B 11/38 (29%), ES121 9/38 (24%). However, 19/38 (50%) were positive for at least one CTA. When 26 melanomas were tested for the expression of six different CTAs 20/26 (77%) were positive for at least one CTA. CONCLUSIONS: CTAs may be useful in the determination of suspected malignancy in cutaneous melanomas. The low incidence of particular CTAs can be overcome by increasing the number of CTAs analysed.
BACKGROUND:Cancer testis antigens (CTAs) are expressed in a variety of malignant tumours. No CTA expression is found in normal adult tissues, except in male germ cells and occasionally placenta. To date, more than 20 CTAs or antigen families have been identified. OBJECTIVES: Owing to their tumour-associated expression pattern, CTAs may be useful for making a distinction between benign and malignant neoplasms. The present study was done to analyse the value of CTAs for the discrimination of cutaneous melanoma and naevi. PATIENTS AND METHODS: Primary melanomas (38) and 19 naevi were analysed for their expression of CTAs by immunohistochemistry using the following monoclonal antibodies (mAb) to the following antigens (mAb/antigen): MA454/MAGE-A1, 57B/MAGE-A4, ES121/NY-ESO-1. In a subset of melanomas (n = 26), the CTA panel was extended to three additional CTAs (mAb/antigen): CT7-33/MAGE-C1, M3H67/MAGE-A3 and GAGE/GAGE. RESULTS: All 19 naevi were negative for the mAbs MA454, M3H67, 57B, ES121, CT7-33 and GAGE. In melanoma, the immunoreactivity was as follows: MA454: 8/38 (21%), 57B 11/38 (29%), ES121 9/38 (24%). However, 19/38 (50%) were positive for at least one CTA. When 26 melanomas were tested for the expression of six different CTAs 20/26 (77%) were positive for at least one CTA. CONCLUSIONS: CTAs may be useful in the determination of suspected malignancy in cutaneous melanomas. The low incidence of particular CTAs can be overcome by increasing the number of CTAs analysed.
Authors: Natko Nuber; Alessandra Curioni-Fontecedro; Claudia Matter; Davide Soldini; Jean Marie Tiercy; Lotta von Boehmer; Holger Moch; Reinhard Dummer; Alexander Knuth; Maries van den Broek Journal: Proc Natl Acad Sci U S A Date: 2010-08-09 Impact factor: 11.205
Authors: Phyu P Aung; Yen-Chun Liu; Leomar Y Ballester; Paul F Robbins; Steven A Rosenberg; Chyi-Chia Richard Lee Journal: Hum Pathol Date: 2013-11-27 Impact factor: 3.466
Authors: Elsa F Velazquez; Achim A Jungbluth; Molly Yancovitz; Sacha Gnjatic; Sylvia Adams; David O'Neill; Kira Zavilevich; Tatyana Albukh; Paul Christos; Madhu Mazumdar; Anna Pavlick; David Polsky; Richard Shapiro; Russell Berman; Joanna Spira; Klaus Busam; Iman Osman; Nina Bhardwaj Journal: Cancer Immun Date: 2007-07-12
Authors: A Curioni-Fontecedro; R Pitocco; N L Schoenewolf; D Holzmann; D Soldini; R Dummer; S Calvieri; H Moch; D Mihic-Probst; A Fitsche Journal: Biomed Res Int Date: 2015-06-16 Impact factor: 3.411
Authors: B Tirosh; V Daniel-Carmi; L Carmon; A Paz; G Lugassy; E Vadai; A Machlenkin; E Bar-Haim; M-S Do; I S Ahn; M Fridkin; E Tzehoval; L Eisenbach Journal: Br J Cancer Date: 2007-12-11 Impact factor: 7.640